29 September 2026
Businesses developing new pharmaceutical, biotech and medical technologies often focus on protecting an invention before publishing research results.
But the patent risk can arise earlier than that.
IP Australia has updated its Patent Examination Manual to clarify that a clinical trial protocol or similar document may be capable of destroying patent novelty even where it describes only a proposed treatment regimen and no trial results have yet been published.
That is an important reminder for anyone planning clinical research.
A disclosure does not necessarily need to prove that a treatment works before it becomes relevant to patentability.
Can a clinical trial protocol be prior art?
Potentially, yes.
Patent novelty generally turns on whether the claimed invention has already been disclosed in relevant prior art.
The recent IP Australia Examination Manual update specifically addresses clinical trial protocols and similar documents. It clarifies that a protocol may be novelty-destroying even if the treatment regimen is only proposed and the results of the clinical trial do not yet exist.
That distinction matters.
Researchers may naturally think that the valuable intellectual property lies in the result: proof that a particular treatment, dose, schedule or combination actually works.
From a patent perspective, however, the earlier description of the treatment itself may already matter.
Why can this create problems for patent applicants?
Clinical research often involves disclosure before final results are available.
Information about a proposed treatment may appear in:
-
clinical trial protocols;
-
trial registrations;
-
research proposals;
-
conference abstracts;
-
scientific publications;
-
ethics or institutional materials that become public;
-
presentations;
-
collaborative research material.
The patent question therefore needs to be considered before publication or public disclosure, not simply when the research team is preparing its final paper.
Once relevant information has entered the public domain, it may become prior art against a later patent application.
Patent timing matters
This is particularly important where an invention develops gradually.
A research team may identify a promising treatment approach, design a clinical trial around it and only later think about patent protection once the results look commercially valuable.
By that point, however, the proposed treatment regimen may already have been publicly disclosed.
That can create a difficult patent position.
The fact that the clinical trial had not yet demonstrated efficacy does not necessarily mean the earlier disclosure can be ignored.
What should businesses and researchers do?
The practical step is not to avoid clinical trials or research publication.
It is to bring patent strategy into the process earlier.
Before a clinical trial protocol, registration or other research disclosure becomes public, consider:
Is there potentially patentable subject matter here?
If there is, determine whether a patent application should be filed before disclosure.
That assessment may need to consider matters such as:
-
treatment methods;
-
dosage regimes;
-
patient groups;
-
combinations of therapies;
-
formulations;
-
medical uses;
-
diagnostic methods;
-
other technical features described in the proposed research.
Not every protocol will disclose a patentable invention, and not every disclosure will destroy novelty.
But leaving the patent question until after trial results are available may be too late.
The broader lesson
Patent protection and publication strategy need to be coordinated.
Researchers understandably think in terms of demonstrating whether an idea works.
Patent law asks a different question: what was already made available before the patent application's priority date?
IP Australia's latest guidance is a useful reminder that those two timelines do not necessarily line up.
For companies, universities and research organisations developing new medical technologies, the safest time to consider patent protection is often before the research is publicly disclosed (not after the results arrive).
